A clinic may advertise a “stem cell treatment” for knee pain, neuropathy, fatigue, autism, lung disease, or memory loss. The phrase sounds medically established, yet FDA approval belongs to a specific manufactured product for a specific use. Approval of one cell therapy does not validate another clinic’s injection, processing method, or disease claim.
That distinction has become more important as legitimate cell therapies have advanced. The United States now has approved blood-forming stem cell products, engineered immune-cell treatments, gene-modified stem cell therapies, and a mesenchymal stromal cell product. Their indications are narrow, their manufacturing is tightly controlled, and they are delivered through specialized medical programs.
What FDA Approval Actually Covers
The FDA reviews a product’s identity, manufacturing controls, clinical evidence, labeling, and proposed use. When approval is granted, it applies to the product and indication in that label. Cells collected from a patient’s fat tissue and injected into a joint are not equivalent to an approved cord-blood product. An umbilical-cord or amniotic-fluid injection sold for back pain does not inherit approval from a separate blood-cancer therapy.
The FDA maintains a current list of approved cellular and gene therapy products. The list includes several different technologies, which is why the broad question “Are stem cells approved?” needs a more precise answer.
Blood-Forming Stem Cells Have Long-Established Uses
Hematopoietic progenitor cells are blood-forming cells that can rebuild the bone marrow and immune system. FDA-licensed cord-blood products are used for disorders affecting blood production and the immune system. Bone marrow and peripheral-blood stem cell transplantation are also established medical practices under specialized transplant standards.
These treatments can be lifesaving, and they carry substantial risk. Conditioning therapy, infection, bleeding, graft failure, organ toxicity, and graft-versus-host disease can occur. A transplant program matches the donor and recipient, prepares the cells, monitors complications, and provides prolonged follow-up. That process bears little resemblance to a same-day wellness-clinic injection.
Engineered Immune Cells Are a Separate Group
Several approved products use a patient’s immune cells that are genetically modified to recognize cancer. CAR T-cell therapies fall in this group. Other products use tumor-infiltrating lymphocytes or engineered T-cell receptors. These treatments are cellular therapies, and some marketing pages loosely group them with stem cells even though their purpose and biology differ.
They are approved for defined cancers after specific prior treatments or clinical circumstances. Risks can include severe immune reactions, neurologic effects, prolonged low blood counts, infection, and secondary cancers. Treatment occurs in centers equipped for close monitoring and emergency management.
Gene-Modified Blood Stem Cells Treat Certain Inherited Diseases
Some approved gene therapies begin with a patient’s own blood-forming stem cells. The cells are collected, modified in a laboratory, and returned after conditioning treatment. FDA-approved examples address specific inherited conditions such as sickle cell disease, beta thalassemia, and certain rare immune or metabolic disorders.
The word “stem” describes the starting cell, while the approval depends on the exact genetic modification and indication. It cannot be generalized to an unapproved infusion that claims to repair many unrelated organs.
Ryoncil Added a New Type of Approved Cell Therapy
In December 2024, the FDA approved remestemcel-L-rknd, sold as Ryoncil, for steroid-refractory acute graft-versus-host disease in pediatric patients age 2 months and older. The product contains allogeneic bone-marrow-derived mesenchymal stromal cells. The FDA product record identifies the exact indication and approval documents.
Ryoncil was the first FDA-approved mesenchymal stromal cell therapy. Its approval did not clear mesenchymal cells for arthritis, tendon injuries, back pain, multiple sclerosis, heart disease, or general rejuvenation. The clinical evidence and manufacturing controls were evaluated for one named product and one serious pediatric condition.
Common Commercial Claims Still Lack Approval
Many clinics sell products made from fat tissue, bone marrow, umbilical cord tissue, Wharton’s jelly, amniotic fluid, or exosomes. A source can sound biological and sophisticated without establishing that the final product is approved. The FDA’s consumer alert on regenerative medicine products warns that products promoted for orthopedic, neurologic, cardiovascular, pulmonary, pain, autism, fatigue, and other uses may be illegally marketed and may pose significant safety concerns.
Potential harms include infection, contamination, unwanted tissue growth, immune reactions, blood clots, tumor formation, and injury from the injection procedure. Financial harm matters too. Patients can spend large amounts on a treatment that delays effective care or makes them ineligible for a legitimate clinical trial.
Exosomes are small packages released by cells. They are being studied as delivery and signaling tools, but a commercial exosome injection should not be presented as an approved shortcut to tissue repair. The FDA has reported serious adverse events associated with unapproved products and states that treatment claims require regulatory review.
How to Verify a Product Before Paying
Ask the clinic for the exact product name, manufacturer, FDA application or license number, approved indication, and official prescribing information. “FDA registered,” “FDA compliant,” and “made in an FDA-inspected facility” do not mean FDA approved. Registration and inspection are different regulatory facts.
A careful verification sequence includes:
- Search the exact product on the FDA’s approved cellular and gene therapy list.
- Open the product page and compare the labeled indication with the condition being treated.
- Ask whether the treatment is part of a clinical trial operating under an FDA-reviewed investigational new drug application.
- Confirm the trial record independently and review the consent form, risks, costs, and alternatives.
- Discuss the offer with a clinician who does not sell the procedure.
A ClinicalTrials.gov listing alone does not prove FDA approval or treatment effectiveness. Early-phase trials may focus on dosing and safety. Some studies do not include a comparison group, and participation can carry unknown risks.
Use the Indication as the Deciding Detail
Cell therapy is a real and rapidly developing field. Its strongest successes have come from precise products, controlled manufacturing, defined patient groups, and careful follow-up. Broad commercial claims erase those details and make experimental care look routine.
Before accepting any stem cell or regenerative treatment, identify the product and its FDA-approved indication. If the clinic cannot provide both in writing, pause. Our overview of regenerative medicine evidence offers additional context for PRP and other procedures, while this approval check answers the first safety question: whether the exact treatment has passed FDA review for the reason it is being offered.